Seroquel
in Dysphoric Hypomania
We are examining the use of quetiapine
(Seroquel) in the treatment of patients currently experiencing both
hypomania and depressive symptoms (dysphoric hypomania). In this study, after an initial
evaluation phase, patients will be instructed to add Seroquel or a placebo to
their current stable medication regimen for a period of eight weeks
while being monitored by a psychiatrist.
Olanzapine
in Bipolar Disorder Exacerbations
We are examining the use of olanzapine
(Zyprexa) in the treatment of patients experiencing increases in symptoms of
bipolar disorder. In this study,
patients will be instructed to add olanzapine or a placebo to their current
stable medication regimen for a period of one week, after which all patients
will receive Zyprexa for one week while being monitored by a psychiatrist.
Depakote
ER in Bipolar Depression
Depakote has become an established treatment for the many manifestations of bipolar disorder, and preliminary data suggest that Depakote has potential efficacy in the treatment of depressive symptoms. In this study, after an initial evaluation, patients will receive Depakote ER for 8 weeks while monitored by a psychiatrist.
Depakote has become an established treatment for the many manifestations of bipolar disorder, and preliminary data suggest that Depakote has potential efficacy in the treatment of depressive symptoms. In this study, after an initial evaluation, patients will receive Depakote ER for 8 weeks while monitored by a psychiatrist.
Uridine
in Bipolar I Depression
The drug being tested in this study, RG2147,
is a type of man-made uridine (uridine is a substance that occurs
naturally in the body). RG2147 may help
in the treatment of bipolar depression.
It is not yet approved to be sold by the FDA. Eligible participants will be instructed to use the
study drug or placebo for 6 weeks while monitored by a psychiatrist using clinical and laboratory
measures. The total length of this
study is up to 14 weeks.
Lamictal
and Abilify in Maintenance Treatment
We are examining the use of Lamotrigine
(Lamictal) in combination with Aripripazole (Abilify) in the
maintenance treatment of Bipolar Disorder.
In this study, patients will take the combination of Lamictal
and Abilify for a period of up to 24 weeks, and then be randomized to either Abilify or placebo
while taking open label Lamictal for a period of up to 52 weeks. To be eligible, participants must have: experienced a recent manic
or mixed episode within 3 months, AND not taken Abilify within the past 3 months.
For these
studies there is no charge for assessment, physician visit, or study
medication.
The Stanford University
Bipolar Disorders Clinic
Bipolar Disorders Clinic
is looking for participants
for the following research studies:
